Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 16/20 | 0.71 |
| ▸ | BRD4 | O60885 | 1/20 | 0.46 |
| ▸ | CCR3 | P51677 | 1/20 | 0.46 |
| ▸ | PTAFR | P25105 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.44 |
| ▸ | FLT3 | P36888 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3723719 | 1.00 | HRH3 (0.71) | HRH3BRD4CCR3PTAFRKCNH2 | |
| SCHEMBL4944562 | 0.93 | HRH3 (0.79) | HRH3BRD4KCNH2 | |
| SCHEMBL4944555 | 0.93 | HRH3 (0.79) | HRH3BRD4KCNH2 | |
| SCHEMBL4944385 | 0.93 | HRH3 (0.71) | HRH3CCR3PTAFRKCNH2 | |
| SCHEMBL3666533 | 0.88 | HRH3 (0.90) | HRH3PTAFRKCNH2 | |
| SCHEMBL4943231 | 0.86 | HRH3 (0.90) | HRH3PTAFRKCNH2 | |
| SCHEMBL3672590 | 0.86 | HRH3 (0.79) | HRH3KCNH2 | |
| SCHEMBL3672593 | 0.86 | HRH3 (0.79) | HRH3KCNH2 | |
| SCHEMBL3670992 | 0.84 | HRH3 (0.79) | HRH3BRD4KCNH2 | |
| SCHEMBL3670994 | 0.84 | HRH3 (0.79) | HRH3BRD4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101778838-A | Azacyclylbenzamide derivatives as histamine-3 antagonists | WYETH CORP | 2010-07-14 | — | — | CN | claimed |
| EP-2155719-A1 | AZACYCLYLBENZAMIDE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | Wyeth LLC (US) | 2010-02-24 | — | — | EP | claimed |
| WO-2008147945-A1 | AZACYCLYLBENZAMIDE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2008-12-04 | — | — | WO | claimed |
| US-20080293771-A1 | AZACYCLYLBENZAMIDE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2008-11-27 | — | — | US | claimed |
| CN-101778838-A | Azacyclylbenzamide derivatives as histamine-3 antagonists | WYETH CORP | 2010-07-14 | — | — | CN | disclosed |
| US-20080293771-A1 | AZACYCLYLBENZAMIDE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293771-A1 | AZACYCLYLBENZAMIDE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | HRH4, HRH3, HRH2 | HRH3 2/4885BRD4 369/4885CCR3 480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.